The Goldman Sachs Group Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics (NASDAQ:TGTX) had its target price upped by The Goldman Sachs Group from $20.00 to $22.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on TGTX. HC Wainwright reaffirmed a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a research report on Wednesday, September 18th. TD Cowen began coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. Finally, B. Riley boosted their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Trading Up 2.7 %

NASDAQ:TGTX opened at $27.90 on Tuesday. The stock has a 50-day simple moving average of $23.73 and a 200-day simple moving average of $20.36. The stock has a market cap of $4.32 billion, a P/E ratio of -278.97 and a beta of 2.19. TG Therapeutics has a 1 year low of $9.81 and a 1 year high of $28.41. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.65% and a negative net margin of 5.42%. The company’s revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.73 earnings per share. As a group, analysts anticipate that TG Therapeutics will post 0.13 earnings per share for the current fiscal year.

Institutional Trading of TG Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TGTX. Swiss National Bank lifted its position in TG Therapeutics by 0.5% during the 1st quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after acquiring an additional 1,500 shares during the period. Quantum Private Wealth LLC lifted its position in TG Therapeutics by 13.7% during the 1st quarter. Quantum Private Wealth LLC now owns 103,604 shares of the biopharmaceutical company’s stock worth $1,576,000 after acquiring an additional 12,523 shares during the period. Sei Investments Co. acquired a new stake in TG Therapeutics during the 1st quarter worth approximately $591,000. Russell Investments Group Ltd. lifted its position in TG Therapeutics by 133.5% during the 1st quarter. Russell Investments Group Ltd. now owns 52,339 shares of the biopharmaceutical company’s stock worth $796,000 after acquiring an additional 29,923 shares during the period. Finally, ProShare Advisors LLC lifted its position in TG Therapeutics by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 24,914 shares of the biopharmaceutical company’s stock worth $379,000 after acquiring an additional 1,961 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.